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Featured Application: Silymarin, a standardized extract derived from seeds and fruits of
Silybum marianum L. Gaertn., is widely used for treatment of various acute and chronic liver
toxicities, inflammation, fibrosis and oxidative stress. The extract has low toxicity and exerts
significant anti-carcinogenic and anti-inflammatory effects. Recently, it has been reported
that the extract is beneficial in type 2 diabetes patients. However, Silymarin is a low water
soluble and low permeable compound, belonging to biopharmaceutical class IV type that faces
stipulated requirements in delivery design. Thus, to overcome these limitations, the extract was
encapsulated into nanostructured lipid carriers. The lipid nanocarriers offer potential applications
as natural, low cost and innovative delivery systems to improve solubility, permeability and
stability of extract. Other advantages are: possibility of controlled drug release and drug targeting,
no biotoxicity of the carrier, biodegradation and no problems with respect to scale-up production
in the food and pharmaceutical fields.
Abstract: Background: Silymarin is the extract from seeds of Silybum marianum L. Gaertn. and it has
been used for decades as hepatoprotectant. Recently, it has been proposed to be beneficial in type 2
diabetes patients. However, silymarin is a poorly water soluble drug with limited oral bioavailability.
In this study, nanostructured lipid carriers were proposed to enhance its solubility and intestinal
absorption. Methods: Nanostructured lipid carriers were made of Stearic acid:Capryol 90 as lipid
mixtures and Brij S20 as surfactant. Formulations were physically and chemically characterized.
Stability and in vitro release studies were also assessed. In vitro permeability and Caco-2 cellular
uptake mechanism were investigated. Results: Obtained results were based on size, homogeneity,
⇣-potential and EE%. Nanostructured lipid carriers could be orally administered. No degradation
phenomena were observed in simulated gastrointestinal fluids. Storage stability of suspensions and
lyophilized products was also tested. Glucose was selected as best cryoprotectant agent. About 60%
of silymarin was released in 24 h in phosphate buffered saline. In vitro parallel artificial membrane
permeability assay experiments revealed that the nanocarrier enhanced the permeation of Silymarin.
Caco-2 study performed with fluorescent nanoparticles revealed the ability of carrier to enhance the
permeation of a lipophilic probe. Cellular uptake studies indicated that active process is involved
in the internalization of the formulation. Conclusions: The optimized nanostructured lipid carriers
showed excellent chemical and physical stability and enhanced the absorption of silymarin.
Keywords: Silybum marianum L. Gaertn.; NLCs; stability; in vitro release; PAMPA; Caco-2; up-take
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1. Introduction
A successful drug carrier system should have optimal drug loading and release properties, a long
shelf life, and exert a much higher therapeutic efficacy as well as lower side effects. Drug delivery
systems are also able to solve several drug problems, including overcoming multi-drug-resistance
phenomenon, penetrating cellular barriers that may limit the intended target site, and improving
in vivo efficacy of the hydrophilic and lipophilic drugs [1–3]. Therefore, nanotechnology could
modulate both drug pharmacokinetics and biodistribution, decreasing potential side effects. In this
context, liposomes are the versatile delivery systems formed by the colloidal association of amphiphilic
lipid substances which are suitable for delivering both hydrophilic and hydrophobic drugs. Recently,
an eco-friendly technology with supercritical fluids for the preparation of nanostructured liposomes
was reported as a green alternative in the scale-up because conventional processes require large
amounts of organic solvents [4]. Liposome-based formulations also represent a good success for dye
delivery, as reported for example in the case of indocyanine green, an FDA-approved fluorescent
dye, utilized in various biomedical applications such as drug delivery, imaging, and diagnosis [5].
Liposomes are also advantageous for encapsulating inorganic structures [6,7].
Recently, the use of herbal medicines has increased due to their therapeutic effects and fewer
adverse effects as compared to modern medicines. However, many herbal extracts show poor in-vivo
activity due to their low solubility, resulting in poor absorption and hence poor bioavailability.
Furthermore, there is a great possibility that many compounds of the extract will be destroyed
partially or entirely after oral administration. Other components might be metabolized by the liver
before reaching the blood circulation.
Novel drug delivery systems represent a valid tool for enhancing bioavailability of herbal drugs.
The novel formulations are reported to have remarkable advantages over conventional formulations of
plant actives and extracts which include increase of solubility, bioavailability, protection from toxicity,
enhancement of pharmacological activity and intracellular uptake, modification of pharmacokinetics
and bio-distribution, improved tissue macrophages distribution, sustained delivery and protection
from physical and chemical degradation. Furthermore, plant extracts present critical issues due to the
wide variety of the compounds contained therein. There are numerous examples of application of the
drug delivery systems in this field related to isolated products or herbal extracts [8–13]. In particular,
oral absorption of lipophilic extract can be significantly improved using lipid-based non-particulate
drug delivery systems, which avoid the dissolution step.
Lipid-based nanocarriers, such as micro- and nanoemulsions, solid-lipid nanoparticles, and
nanostructured lipid carriers, represent successful examples of nanoformulations applied to overcome
the limitations of natural compounds [14–16]. They can ameliorate solubility, stability, permeation and
bioavailability. Lipid-based drug delivery systems are composed by lipids that are also absorption
enhancers [17,18] and can be developed in small particle sizes ranging frommicro- to nanometers [19,20]
to increase the absorption in the hydrophilic environment of the gastrointestinal tract.
Among lipid-based delivery systems, nanostructured lipid carriers (NLCs) offer many advantages,
such as long-term stability, increased bioavailability of encapsulated active ingredient, possibility to
obtain a controlled or targeted release, versatility in encapsulating both lipophilic and hydrophilic
drugs, and high efficiency of encapsulation [21]. NLCs combine two features: they are colloidal carriers
of submicron size and they are composed of a solid-lipid core consisting of a mixture of solid lipids
blended with a liquid lipid to form a nanosized unstructured matrix and an aqueous phase containing
a surfactant or a mixture of surfactants. The partially solid nanostructure enhances the stability of
entrapped bioactive, enables high loading capacities, and offers sustained release profiles. The lipid
matrix is made of biocompatible and biodegradable materials, which decrease the risk of acute or
chronic toxicity. All the components are commercially available and/or approved by regulatory
agencies [22–25].
Silymarin (SLM) is one of the oldest traditional herbal medicines used to treat different disorders.
SLM is mainly composed of four flavonolignan isomers: silybin, isosilybin, silychristine and
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silydianin [26,27]. Hepatoprotective effects of SLM have been demonstrated. It is mildly toxic and
exerts significant anti-carcinogenic and anti-inflammatory effects. Recently, its beneficial effect in type
2 diabetes patients has been reported and a number of articles demonstrated its ability to decrease both
fasting and mean daily glucose, triglycerides and total cholesterol levels [28,29]. Antidiabetic effect of
SLM is attributed to inhibition of gluconeogenesis in the liver and decrease of glucose-6 phosphatase
activity [30]. However, it is a low water soluble and low permeable biopharmaceutic class IV type
compound that faces stipulated requirements in delivery design.
The aim of the study was to investigate the possibility to delivery lipophilic SLM into NLCs
for the preparation of oral dosage form. NLCs were characterized in terms of average diameter,
polydispersity, ⇣-potential, morphology, and physical and chemical stability. The free-drying process
was also considered to increase long-term storage stability of the formulation.
Storage stability and in simulated gastrointestinal conditions was also assessed. SLM in vitro
release was studied in different pH media. The release results were applied to define the kinetic and
mechanism of SLM release from the NLCs.
The ability of NLCs to ameliorate the permeability of SLM was evaluated in vitro by using parallel
artificial membrane permeability assay (PAMPA). Fluorescent nanoparticles were also prepared to verify
the capacity of NLCs to enhance the permeability across Caco-2 cells layer. Preliminary cytotoxicity
studies were conducted to confirm the optimized biopharmaceutical properties of the lipid carrier.
The data obtained from the in vitro tests were compared to elucidate the permeation/absorption
mechanism of SLM, which further could be correlated to in vivo behavior. Caco-2 cellular uptake,
with or without endocytic inhibitors, was also evaluated, to identify the possible mechanisms of the
internalization pathway of the developed NLCs.
2. Materials and Methods
2.1. Materials
Stearic acid, Brij S20, Fluorescein isothiocyanate (FITC, purity   90%, HPLC), Silymarin (SLM),
Silibin (Sb, purity   98%, HPLC), Sodium chloride (NaCl), Lipase from porcine pancreas, Pepsin
from porcine gastric mucose, Bile salts, Sodium Hydroxide (NaOH), Calcium chloride (CaCl2),
Cholesterol, Lecithin, Phosphate buffered saline (PBS) bioperformance certified, Mucin from porcine
stomach, Sodium azide, Chlorpromazine, Indomethacin, DL-↵-Tocopherol acetate (Vitamin E),
D-Mannitol, D(+)-Glucose anhydrous, Acetone high performance liquid chromatography (HPLC)
grade, Acetonitrile HPLC grade, Methanol HPLC grade, Dimethyl sulfoxide (DMSO) HPLC grade,
Formic acid analytical grade, Hydrochloric acid (HCl) analytical grade, and 1,7-octadiene 98%,
Dichloromethane (CH2Cl2) were purchased from Sigma-Aldrich (Milan, Italy). Capryol 90, Lauroglycol
90, Labrafac PG, Labrafac WL 1349, Labrafil M 1944 CS, and Precirol ATO 5 were a gift of Gattefossé
(Saint Priest, France). Oleic acid was purchased from Carlo Erba Spa (Milan, Italy). Hemp oil and
borage oil were from Galeno srl (Comeana, Prato, Italy). Water was purified by a Milli-Qplus system
fromMillipore (Milford, CT, USA). Phosphotungstic acid (PTA) was from ElectronMicroscopy Sciences
(Hatfield, PA, USA). The 96-well Multi-Screen PAMPA filter plates (pore size 0.45 µm) were purchased
from Millipore Corporation (Tullagreen, Carrigtwohill, County Cork, Ireland). Dialysis kit was from
Spectrum Laboratories, Inc. (Breda, The Netherlands).
2.2. Screening of Liquid Lipids
The ability of different liquid lipids (oils) to solubilize SLM was evaluated in order to increase the
encapsulation efficiency the NLCs [18]. The solubility of SLM was determined by adding an excess
amount of SLM into an exact volume of each selected vehicle while keeping at 500 rpm for 24 h at room
temperature. Further the samples were centrifuged at 14,000 rpm for 10 min. The supernatants were
diluted with methanol or with methanol/dichloromethane (3:2 v/v or 1:1 v/v) mixture and finally
analyzed with HPLC consisting of an HP 1100 Liquid Chromatograph with a diode-array-detector
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(DAD) and controlled with a HP 9000 workstation (Agilent Technologies, Santa Clara, CA, USA).
A RP-C18 Luna Omega Polar (150 mm ⇥ 3 mm, 5 µm) (Agilent Technologies) analytical column was
used. The mobile phases were: (A) formic acid/water pH 3.2; (B) acetonitrile; and (C) methanol with
0.4 mL/min flow rate. The multi-step linear solvent gradient applied was: 0–2 min 10% B and 10% C;
2–6 min 15% B and 22% C; 6–11 min 20% B and 30% C; 11–16 min 30% B and 40% C; 16–18 min 30% B
and 40% C; 18–20 min 40% B and 40% C; 20–23 min 40% B and 40% C; 23–27 min 10% B and 10% C;
equilibration time 8 min; oven temperature 25  C. The chromatograms were registered at a wavelength
of 288 nm. The calibration curve was prepared using standard silibinin, dissolved in methanol from a
concentration range of 0.001–0.100 µg/µL.
2.3. Preparation of NLCs
The NLCs were prepared by the emulsion–evaporation method at high temperature and
solidification at low temperature [31]. The lipid phase, composed of Stearic Acid (80 mg, solid lipid)
and Capryol 90 (20 mg, liquid lipid) was dissolved into 5 mL of acetone and heated under magnetic
stirring. The resulted organic solution was added dropwise into the aqueous phase containing Brij S20
(200 mg in 30 mL) at 1000 rpm and 75  C to induce the acetone evaporation. Further, the concentrated
emulsion was quickly added into an equal volume of cold distilled water in an ice bath under fast
stirring at 1000 rpm for 1 h to induce NLCs formation. The obtained NLCs were harvested and stored
at 4  C. The final concentrations of stearic acid, Capryol 90 and Brij S20 were 0.57% w/v, 0.14% w/v
and 1.43% w/v, respectively.
2.4. Preparation of SLM-Loaded NLCs and FITC-Loaded NLCs
The SLM-loaded NLCs (SLM-NLCs) and the fluorescent NLCs (FITC-NLCs) were prepared
according to the method previously described [31]. Fluorescein isothiocyanate (FITC) (lex = 492 nm,
lem = 518 nm, green) or SLM were added to lipid phase to obtain a final concentration of 0.04% w/v
for FITC and 0.29% w/v for SLM. Further the formulations were hermetically sealed and stored at 4  C,
protected from light. In addition, the SLM-NLCs sample was divided into three parts: one of these
was frozen with liquid nitrogen and then moved to the freeze-drier [32]. The other two were freeze
dried after the addition of D-Glucose anhydrous (10% w/v) or D-Mannitol (10% w/v) as cryoprotective
agents. The drying time was 24 h. The reaction yields were calculated as the weight percentage of
freeze-dried formulations, with respect to the total weight of the substances used for the preparation.
2.5. Particle Size, Polydispersity Index and z-Potential
The evaluation of the particle size and the polydispersity index (PDI) was performed by dynamic
light scattering using a Zsizer Nanoseries ZS90 (Malvern Instrument, Worcestershire, UK) at a fixed
angle of 90  and at 25  C. The ⇣-potential, indicating the electric charge on the NLCs surface and the
physical stability of the formulations, was calculated using the Helmholtz–Smoluchowsky equation
using the same instrument. To avoid multiple scatterings of the light, for all measurements, samples
were diluted to suitable concentration with distilled water. The analyses were performed in triplicate.
2.6. Transmission Electron Microscopy
The shape and the surface structure of NLCs were investigated by transmission electron
microscope (TEM, Jeol 1010, Tokyo, Japan). The samples were opportunely diluted with distilled
water, then were dropped on a 200 mesh carbon film-covered copper grid and negatively stained with
phosphotungstic acid aqueous solution (1% w/v). After drying, the grid containing the sample was
observed with the TEM [14].
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2.7. Determination of Encapsulation Efficiency and Recovery
Dialysis bag method was applied to remove free SLM (or FITC) from the formulations. The bag
was inserted for 1 h in 1 L of distilled water, with the aim to determine the encapsulation efficiency of
the NLCs. Then, the sample was diluted (1:10 v/v) with methanol and sonicated in an ultrasonic bath
for 30 min to extract SLM (or FITC). The resulted mixture was centrifuged for 10 min at 14,000 rpm and
analyzed by HPLC [33]. FITC analyses were performed on the same apparatus, with the column used
for SLM. The eluents were: (A) formic acid/water pH 3.2; and (B) acetonitrile. The gradient applied
was: 0–2 min 20% B; 2–22 min 20–85% B; 22–25 min 85–100% B; 25–28 min 20% B; equilibration time
7 min; temperature 25  C; flow rate 0.4 mL/min. In this case, the chromatograms were acquired at
224 nm. The linearity range of responses of Sb and FITC dissolved in CH3OH was determined on five
concentration levels from 0.001 µg/µL to 0.054 µg/µL.
The encapsulation efficiency was calculated by the following Equation (1):
Encapsulation e f f iciency =
SLM (or FITC) encapsulated
Total SLM (or FITC)
⇥ 100 (1)
The recovery was estimated following the same procedure but without dialysis purification and
was calculated by using the following Equation (2):
Recovery =
SLM (or FITC) detected




Stability studies on particle size, PDI, ⇣-potential and encapsulation efficiency of SLM-NLCs
as suspension at 4  C and freeze-dried SLM-NLCs stored at room temperature were conducted at
Days 0, 10, 20 and 30 from the production by light scattering and HPLC analyses. Phase separation
and turbidity were also investigated in the case of the suspension, while the freeze-dried NLCs were
evaluated for the appearance of the powder and for the redispersibility time.
2.8.2. Stability in Simulated Gastrointestinal Conditions
The NLCs sample was incubated in an equal volume of simulated gastric fluid (SGF) for 2 h at
37  C and subsequently in simulated intestinal fluid (SIF) for further 2 h at 37  C. SGF was prepared
dissolving pepsin (0.32% w/v), 2 g of sodium chloride and 7 mL of HCl in 1 L of distilled water. The pH
of the solution was adjusted to 2.0 with HCl 1 M. The composition of SIF was: lipase (0.04% w/v),
bile salts (0.07% w/v), pancreatin (0.05% w/v) and calcium chloride 750 mM. The pH was adjusted to
7.0 with NaOH. The effect of SGF and SIM on physical properties of NLCs was evaluated by measuring
particle size and PDI.
2.9. In Vitro Release
In vitro release of SLM from NLCs was investigated using the dialysis bag method. Regenerated
cellulose membranes with a MWCO of 3–5 kD were used to retain the NLCs and allow the diffusion
of SLM into the release medium. Phosphate buffer saline (PBS, pH 7.4), SGF without pepsin and
enzyme-free SIF were taken as dissolution medium. Two milliliters of SLM-loaded NLCs were
deposited into the dialysis membrane and placed in 200 mL of release medium at 37  C with stirring at
150 rpm. At definite time intervals up to 24 h, 1 mL was withdrawn and replaced with fresh dissolution
medium. SLM released was quantified by HPLC.
For evaluating the kinetic and mechanism of drug release from the liposomes, Korsmeyer–Peppas
model, Hixson–Crowell model, Higuchi model, and first- and zero-order mathematical models were
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used and best fitted model was selected based on high regression coefficient (R2) value for the
release data.
2.10. PAMPA Experiments
The permeation of SLM alone and SLM-NLCs through artificial membranes was determined
using the protocol optimized in our previous studies [10,15,16,34]. The 96-well microtiter PVDF filter
plate was impregnated with 10 µL of a lecithin (1% w/v) and cholesterol (0.8% w/v) in 1,7-octadiene
solution. Then, the donor plate was filled with 250 µL of SLM solution or SLM-NLCs and placed
upon the acceptor plate containing 250 µL of 5% v/v DMSO in PBS. The plate assembly was placed
into a sealed container to prevent evaporation and incubated at room temperature for 4 h. After the
incubation, the samples were diluted with methanol, sonicated in an ultrasonic bath for 30 min and
centrifuged for 10 min at 14,000 rpm for HPLC analyses. The permeability of SLM and the recovery
value were calculated according to Equations (3)–(5) reported in the literature [35,36]:





; where C =
VD ⇥VA
(VD +VA)⇥ A⇥ t ; (3)
[Compound]eq =




[Compound]D ⇥VD + [Compound]A ⇥VA
([Compound]D0 ⇥VD
⇥ 100 (5)
where Pe is the effective permeability (cm/s); A is the effective filter area (cm2); VD and VA are the
volumes in the acceptor and the donor plates (mL), respectively; t is incubation time (s); [Compound]A
and [Compound]D are the concentrations of SLM in the acceptor and the donor plates at time t,
respectively; and [Compound]D0 is the concentration of SLM in the donor plate at time 0.
2.11. Caco-2 Cell Culture Experiments
2.11.1. Cell Lines
The colorectal adenocarcinoma cell line Caco-2 was purchased fromAmerican Tissue Type Culture
Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (Thermo Fisher
Scientific, Rodano, Milan, Italy) with 20% fetal bovine serum (FBS) (Thermo Fisher Scientific, Rodano,
Milan, Italy), 100 U/mL penicillin-streptomycin (Thermo Fisher Scientific, Rodano, Milan, Italy) in 5%
CO2 at 37  C.
2.11.2. Cell Culture Experiments
AnMTS assay was used to determine the cell viability after exposure to NLCs for 2 h, as previously
described [37]. The relative cell viability was expressed as a percentage of the untreated control group.
2.11.3. Transport Studies
For the permeation studies, Caco-2 cells were seeded into 12-well PET transwell plates
(1.13 cm2 growth surface area and pore size 0.4 µm, Greiner Bio-One, Milan, Italy) at a density
of 2 ⇥ 104 cells/cm2 and grown for 21 days to form a confluent monolayer. The integrity of the cellular
barrier was assessed using Lucifer Yellow permeability test [16]. Samples of media were collected
from the basal compartment of each transwell plate and replaced with fresh HBSS at 0 (before sample
addition), 30 and 60 min. The FITC concentrations of these samples were determined by HPLC and
adjusted to reflect the change in volume at each successive sampling point. LY measurements were
also taken at the end of the experiment.
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2.11.4. Uptake Studies
To identify the transepithelial transport mechanism, Caco-2 cells were pre-incubated with sodium
azide (an ATP synthesis inhibitor, 1 µM), chlorpromazine (a clathrin blocker, 15 mM), and indomethacin
(a caveolin-dependent endocytosis inhibitor, 25 mM) for 30 min followed by addition of NLCs 1:180 for
1 h, or maintained at 4  C during the NLCs exposure. At the end of the treatments, the amount of FITC
was measured on cellular lysate by HPLC analysis. In parallel, Caco-2 cells, grown on histological
slides, were treated in the same condition, fixed in 4% formaldehyde in 0.1 mol/L phosphate buffer,
pH 7.4, for 10 min and observed by fluorescence microscopy (Labophot-2 Nikon, Tokyo, Japan).
Ten photomicrographs were randomly taken for each sample and fluorescence was measured using
ImageJ 1.33 image analysis software (http://rsb.info.nih.gov/ij).
3. Results and Discussion
3.1. NLCs Preparation and Characterization
The selection of the components for NLCs preparation is important to obtain good stability of the
formulation and high encapsulation efficiency of the extract. For this purpose, solubility studies of
SLM in different liquid lipids (Table 1) have been performed. The selected excipients are approved
and recognized as safe substance, as the purpose of this study is to produce formulations suitable for
oral administration.
Table 1. Solubility of silymarin (SLM) in different liquid lipids/oils. Results are expressed as means ±
standard deviation, n = 3.
Liquid Lipid SLM Solubility (mg/mL)
Borage oil 0.12 ± 0.01
Capryol 90 13.80 ± 0.14
Hemp oil 0.13 ± 0.01
Labrafac PG 0.77 ± 0.01
Labrafac WL 1349 0.72 ± 0.09
Labrafil M 1994 2.10 ± 0.15
Lauroglycol 90 10.00 ± 0.01
Oleic acid -
Vitamin E 0.53 ± 0.15
As evidenced in Table 1, the solubility of SLM in the various analyzed liquid lipids is always
greater than in water (0.26 mg/mL), except in the case of borage and hemp oil. The best result was
obtained using Capryol 90 (13.80 mg/mL) and Lauroglycol (10.00 mg/mL).
Capryol 90 is a colorless liquid with HLB of 5, consisting of mono propylene glycol/esterified
with caprylic acid and used for oral, topical, rectal and vaginal formulations. Lauroglycol 90 is an oil
with HLB equal to 3, consisting of mono/di-esterified propylene glycol with lauric acid and used as an
excipient for topical and oral pharmaceutical formulations.
The choice of lipids and surfactants used for NLCs formulation was performed by evaluating
not only the solubility of SLM, but also the HLB of oils and tensides, with the aim to obtain good
encapsulation efficacy and high stability of the carriers. Stearic acid and Precirol ATO were tested as
solid lipids, Capryol and Lauroglycol as liquid lipids. Among the surfactants, selected hydrophilic
compounds were Tween 80 (HLB 15), Tween 20 (HLB 16.7) and Brij S20 (HLB 15). These tensides were
chosen based on the HLB value and solubilizing capacities.
Different ratios of solid and liquid lipids and tensides were evaluated. Some tested formulations
showed good physical requires for oral administration, such as size and PDI, but they were not stable.
Finally, the optimized NLCs are reported in Table 2. Its composition was Stearic acid/ Brij S20 (1:2 w/w)
and Capryol 90 (2:8 w/w respect to solid lipid). Brij S20 is a non-ionic tenside, derived from stearic
acid covalently grafted with PEG 1000, which form a hydrophilic steric barrier around the NLCs
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and increase their stability [14]. This selected formulation was able to load 40 mg/mL of extract
(SLM-NLCs), with an EE% of 92.4%. The presence of SLM does not influence the stability of the NLCs:
when SLM were loaded into the nanoparticles, the formulation showed the same physical parameters
than empty NLCs. TEM micrographs provided information on morphology and dimensions of
nanoparticles: the formulation had a spherical structure with a diameter like that obtained through
DLS analyses (Figure 1).
FITC, a lipophilic fluorescent dye, was incorporated into NLCs as a probe to perform in vitro
studies with Caco-2 cells and to elucidate trans-endothelial transport. Fluorescent NLCs were prepared
as reported for empty NLCs, by adding FITC to the lipid phase (FITC-NLCs). Their physical and
chemical parameters are shown in Table 2. All formulations are useful for oral administration.
The high ⇣-potential confirms their stability, as also supported by colloidal stability data.
Furthermore, the method applied for the preparation of the NLCs allows avoiding the degradation
of the loaded extract or probe, as evidenced by the high recovery values (Table 2).
Table 2. Physical and chemical properties of emptyNLCs, SLM-NLCs and Fluorescein isothiocyanate-NLCs





(mV) EE (%) Recovery (%)
NLCs 194.5 ± 3.7 0.24 ± 0.02  36.0 ± 0.9 - -
SLM-NLCs 213.6 ± 16.0 0.17 ± 0.04  31.6 ± 0.5 92.4 ± 4.1 94.8 ± 1.8
FITC-NLCs 215.0 ± 0.3 0.24 ± 0.01  37.4 ± 0.9 95.7 ± 1.2 98.5 ± 0.5
 
Figure 1. Transmission Electron Microscope (TEM) images of Silymarin (SLM)-NLCs.
Then, the SLM-NLCs were freeze-dried in the presence of a cryoprotectant, both to prolong its
physical and chemical stability over time, and to reduce microbial contamination. From the literature,
different cryoprotectants, are reported, such as glucose, maltose, trehalose, sucrose, mannitol and
lactose, from 5 to 20% w/v [38]. Glucose (10% w/v) and mannitol (10% w/v) were tested for the NLCs
(Table 3).
A sample of SLM-NLCs was lyophilized without cryoprotectant, while two other samples in the
presence of glucose and mannitol, respectively. The dispersions were physically characterized with
DLS after resuspension with water. The results (Table 3) highlighted a significant increase in size and
PDI values in the absence of cryoprotectant. On the contrary, the lyophilization with glucose allowed
preserving the stability of the system providing nanoparticles with almost identical dimensions and
homogeneity those detected before the freeze-drying process. Finally, the nanoparticles lyophilized
with mannitol revealed a certain increase in terms of average diameter and inhomogeneity.
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Table 3. Physicochemical characterization and reaction yields of SLM-NLCs after freeze-drying process.
Light Scattering and High performance liquid chromatography (HPLC) analyses were performed after
reconstitutions of the samples in water. Results are expressed as means ± standard deviation, n = 3.
Freeze-Dried Product Particle Size (nm) PDI ⇣-Potential (mV) EE (%) Yield (%)
SLM-NLCs 383.6 ± 4.7 0.32 ± 0.03  30.1 ± 0.8 64.1 ± 0.2 97.8 ± 0.1
SLM-NLCs + Glucose 205.2 ± 2.7 0.16 ± 0.04  36.7 ± 0.5 87.6 ± 4.9 98.9 ± 0.2
SLM-NLCs + Mannitol 305.1 ± 9.5 0.24 ± 0.01  32.6 ± 0.7 76.0 ± 3.1 99.2 ± 0.1
The results confirm the advantage of cryoprotectants in preventing the aggregation of
nanoparticles during the lyophilization process. In particular, glucose allows obtaining a freeze-dried
product easily re-dispersible, soft and voluminous. In fact, the cryoprotectants interact with the polar
portions of surfactants, forming a kind of protective coating. They also reduce the crystallization
processes, favoring the amorphous state of the frozen sample [38].
3.2. Chemical and Physical Storage Stability
After four weeks at 4  C, SLM-NLCs suspensions were chemically and physically stable. No changes
in size and homogeneity occurred: dimensions were 200.3 ± 2.6 nm with PDI of 0.10 ± 0.03.
The ⇣-potential was monitored up to 30 days of storage, and no significant evolution was found, with
final value of  24.3 ± 0.7 mV. Furthermore, EE% and recovery% did not decrease during storage (EE%
86.7 ± 2.4; recovery% 89.3 ± 1.2). Thus, developed formulations are able to prevent the degradation of
incorporated compound. This represents an important result, considering that, in many cases, chemical
and physical instabilities were observed when NLCs were stored as aqueous suspension due to lipid
crystallization, polymorphic transformations, aggregation phenomena and hydrolysis processes.
Analogous study was performed on freeze-dried products. Both products maintain the
same physical characteristics as before freeze-drying (size 216.7 ± 4.7 nm, PDI 0.34 ± 0.01 and
 35.2 ± 1.3 mV, in the case of glucose; and size 300.1 ± 2.1 nm, PDI 0.28 ± 0.01 and  33.0 ± 0.1 mV,
in the case of mannitol) but there is a small decrease in EE% (79.8 ± 2.5 for glucose and 73.5 ± 1.2 for
mannitol). Recovery for both formulations is more than 80%.
3.3. Stability in Simulated Gastrointestinal Fluids
NLCs have been formulated not only for increasing bioavailability of the SLM but also to
protect the active components from degradation during gastrointestinal transit. The integrity of the
nanoparticles can represent an important prerequisite to reach the sites of absorption in the intestine
and obtain increased uptake at the intestinal epithelium itself [39]. For this purpose, the physical
stability of the formulation in simulated gastrointestinal conditions was determined by subjecting it to
simulated gastric digestion at pH 2.0 in presence of pepsin, followed by simulated intestinal digestion
in presence of the pancreatin-lipase-bile salts mixture.
After 2 h of incubation in SGF followed by 2 h of incubation in SIF, NLCs resulted stable and
no aggregation or degradation phenomena occurred (Table 4). This stability in acidic and intestinal
conditions may be due to the effect of steric stabilization of nonionic surfactant, Brij S20, which
decreases the flocculation and coalescence phenomena with its molecular structure. In addition, this
stability can be conferred also by the properties of lipids, Stearic acid and Capryol 90, able to protect
encapsulated SLM by enzymatic degradation and by pH conditions [40].
Table 4. Physical stability of SLM-NLCs in simulated gastrointestinal fluids (SGF: simulated gastric
fluid; SIF: simulated intestinal fluid). Results are expressed as means ± standard deviation of
three experiments.
Medium Size PDI
SGF 258.4 ± 3.9 0.34 ± 0.05
SIF 205.2 ± 2.8 0.28 ± 0.10
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3.4. In Vitro Release
In vitro release studies were performed in different pH media without enzymes: PBS, SGF (pH 2)
and SIF (pH 7). The studies have been conducted to evaluate if and how different pH conditions
can influence the release of SLM from the NLCs. The in vitro release profiles are shown in Figure 2.
In PBS, the absence of the burst effect is evident: the release of SLM is not immediate but gradual, up
to a maximum percentage of 66.3% in the 24 h.
In the gastric environment during the first 2 h, corresponding to transit through the stomach, only
the 9.6% of the SLM, was released. Thus, the developed NLCs remain intact in SGF, according to the
previous data of the stability study, and they prevent degradation of the encapsulated extract and can
be promising carriers for the transport of a large amount of SLM into the intestine.
In simulated intestinal environment, a controlled release of SLM with a maximum of 15.4%
released within 24 h was observed. These results suggest that, following the gastrointestinal tract
transit, 84.6% of SLM remains encapsulated in NLCs, allowing greater intestinal absorption.
The lower release obtained in simulated gastro-intestinal conditions suggests that the formulation
protects SLM from degradation and guarantees a slow release of the extract due to the lipid matrix.
NLCs demonstrated promising potential to prevent burst release and degradation of SLM which
remained entrapped into nanoparticles and could be absorbed and reach the target site after oral
administration [41]. The absence of the burst effect can be justified by the low percentage of liquid
lipid which does not lead to the formation of an outer shell containing high concentrations of SLM,
but the oil is distributed randomly in the solid lipid matrix [42]. Such a prolonged release can allow
increased absorption of the drug, maintaining a constant concentration in the plasma.
 
Figure 2. In vitro release studies of SLM-NLCs in phosphate buffered saline (PBS) pH 7.4 (black line)
and in simulated gastrointestinal fluids (dark grey line and light grey dotted line). Results are expressed
as means ± standard deviation, n = 3.
Different theoretical models were considered to examine the nature of release. Drug release
mechanism in PBS was defined by fitting SLM release data during 24 h to various kinetics
models. By comparing the regression coefficient values (Zero-order: 0.8263; First-order: 0.9304;
Korsmeyer–Peppas: 0.7578; Hixson: 0.8998; Higuchi: 0.9664), the Higuchi model was shown to be
the most adequate to describe the kinetics of NLCs. Thus, the diffusion process controlled the release
mechanism. Furthermore, if analyzed according to Korsmeyer–Peppas model, the release exponent n
was >0.89, and it confirms that the release follows a super case II drug-transport mechanism and the
mechanism can be inferred to follow a non-Fickian diffusion process.
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3.5. PAMPA Studies
The PAMPA is an in vitro method used to estimate transcellular passive permeability. It is
considered robust, reproducible and fast [43]. The assay could be applied not only in the preformulation
studies of single molecules but also for complex matrices such as plant extracts [39] and compounds
loaded into formulations, i.e., SLNs and microemulsions [15,16,33,34,44].
Considering that most compounds reach the blood stream by passive mechanism, PAMPA could
be a helpful complement to Caco-2 assay to predict the oral absorption of SLM.
The effective permeability (Pe) value after 4 h of incubation was 12.1 ± 1.4 ⇥ 10 6 for free SLM
and 132 ± 11 ⇥ 10 6 in the case of extract loaded NLCs. Passive permeation of SLM was improved
considerably with respect to aqueous solution (11-fold higher) when formulated. The recovery was
100% for the SLM-NLCs and 95% for the saturated aqueous solution of SLM. A high recovery value,
above 80% is a proof of an acceptable permeation prediction. Moreover, this result suggests that there
was neither relevant extract membrane retention nor binding to the surface of the filter. The developed
formulations represent a successful attempt to ameliorate passive permeation of SLM.
3.6. Caco-2 Cell Culture Experiments
Permeation studies were performed using a cell-based model in order to complete in vitro
characterization of NLCs and understand oral absorption mechanisms. For this aim, Caco-2 cells
are considered the most predictive in vitro model to estimate not only passive intestinal diffusion, as
previously described for PAMPA, but also active transport processes, paracellular permeability and
active efflux [10,15,16].
The cytotoxicity of FITC-NLCs was first investigated by MTS test with the aim to select the
most appropriate concentration for transport studies. As shown in Figure 3, NLCs exerted a quite
low cytotoxicity (about 30%) diluted 1:180. This is a good result considering that NLCs undergoes a
dilution from 1:200 to 1:1000 when they are oral administered.
Thus, the transport studies were conducted by using this dilution and 1 h as exposition time.
 
Figure 3. Viability of Caco-2 cells exposed to Fluorescein isothiocyanate-NLCs (FITC-NLCs) (1:20 to
1:180), for 2 h.
Papp values are reported in Figure 4; it can be observed that the permeation of FITC, a lipophilic
probe not able to cross the Caco-2 monolayer, was improved when formulated into NLCs, reaching
an apparent permeability of 102.4 ⇥ 10 6 cm/s after 30 min.
To investigate the possible pathways of FITC-NLCs internalization in Caco-2 cells, its uptake was
followed in different energetic conditions and in presence of endocytosis inhibitors.
The representative images in Figure 5a showed that the internalization of the FITC-NLCs was
significantly reduced when incubated at different energetic conditions (4  C and ATP-depleted
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condition). The experimental results indicated in fact that the cellular uptake of NLCs at 4  C was only
about 37% of that at 37  C and sodium azide (an energy inhibitor) was also able to reduce, although to
a lesser extent, the cellular uptake. At low temperatures, a higher rigidity and a lower permeability of
lipid bilayer have been demonstrated and could explain this difference [45].
 
Figure 4. Apparent permeability coefficient (Papp) of free FITC or loaded into NLCs (FITC-NLCs) across
the Caco-2 monolayer after 1 h of incubation.
 
 
Figure 5. (a) Cellular uptake of FITC-NLCs (green staining), in the presence of endocytic inhibitors.
Nuclei were stained with DAPI. Final magnification 400⇥; scale bar 20 µm. (b) Percentage of
intracellular FITC in Caco-2 cells after 1 h of exposure to FITC-NLCs at 37  C (100%) or in the presence
of endocytic inhibitors. Results are expressed as means ± standard deviation, n = 3.
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The dependency of cellular uptake on energy indicates that the internalization possibly occurs
by endocytosis. To further illustrate about the particular internalization pathway involved, Caco-2
cells were pretreated with inhibitors: chlorpromazine blocks clathrin-dependent endocytosis and
indomethacin inhibits caveolin-dependent endocytosis. The cellular uptake of FITC-NLCs seems to be
a rather complex process not dependent solely on a single mechanism. Our results indicated that they
are incorporated into the intestinal epithelia mainly via the caveolin-dependent endocytic pathway,
whereas the endocytosis mediated by clathrin was less involved in the uptake, reducing it by about
20% (Figure 5b).
4. Conclusions
These studies confirmed that the developed NLCs offer a promising delivery system for enhancing
the solubility and intestinal permeability of lipophilic SLM.
Stearic acid, Capryol and Brij S20 were chosen as solid lipid, liquid lipid and non-ionic surfactant,
respectively. Based on obtained results of physical and chemical characterizations, developed
formulations could be orally administered. The system showed excellent chemical and physical
stability during storage at 4  C and after incubation into simulated gastrointestinal environment.
In vitro release indicated that NLCs may prevent burst release and gastric degradation of SLM.
Moreover, the slow release of SLM suggests homogeneous entrapment of the compound throughout
the lipid matrix.
Caco-2 cells were selected to form simulative intestinal epithelial cell monolayers to study the
permeation and the related transport mechanisms. The results indicated that the formulations were
successful in enhancing the permeation of SLM and that the transport of the NLCs across the cell
monolayer is energy-dependent and mediated by clathrin- and caveolae (or lipid raft)-related routes.
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